This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Total Anomalous Pulmonary Venous Connection, TAPVC전체 폐정맥연결이상

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q26.2 (Total anomalous pulmonary venous connection)  |  Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsTotal anomalous pulmonary venous return (TAPVR), total anomalous pulmonary venous drainage, Total Anomalous Pulmonary Venous Return (TAPVR), total anomalous pulmonary venous connection
C. Adult onsetSurvival to adulthood without corrective surgery is extremely rare, and after surgery, follow-up in adulthood is needed for late complications such as recurrent pulmonary vein stenosis, atrial fibrillation, and pulmonary hypertension.
1. HistoryFirst described by Brody in 1942, first surgical attempt by Muller in 1951, successful complete repair under cardiopulmonary bypass by Lewis and Varco in 1956
2. CausesFailure of the common pulmonary vein to join the left atrium during embryonic development; combined action of genetic and environmental factors
3. GeneticsAssociated with various genetic abnormalities, including 22q11.2 microdeletion, PDGFRA variants, and CFC1 variants
4. General epidemiology5.9~7.1 per 100,000 live births, accounting for about 1~3% of all congenital heart disease
5. PathophysiologyAll pulmonary veins connect to systemic veins or the right atrium instead of the left atrium, so oxygenated blood mixes in the right atrium
6. SymptomsCyanosis, tachypnea, feeding difficulty, symptoms of heart failure, severe respiratory failure with pulmonary venous obstruction
7. SignsAccentuated and fixed split second heart sound, heart murmur, right ventricular hypertrophy, cardiomegaly, signs of pulmonary edema
8. ScreeningPrenatal fetal echocardiography, newborn pulse oximetry screening
9. DiagnosisAnatomical subtype and presence of pulmonary vein stenosis confirmed by echocardiography, cardiac CT, MRI, and cardiac catheterization
10. TreatmentEarly surgical repair in the neonatal period is the standard treatment; the sutureless technique reduces restenosis
11. PrognosisSurgical mortality less than 5% (non-obstructed type); poor prognosis when pulmonary vein restenosis occurs
12. PreventionStrengthening prenatal diagnosis, genetic counseling, folic acid supplementation, establishing a system for prompt surgery after birth
13. ReferencesTotal anomalous pulmonary venous connection in 80 patients: Primary sutureless repair and outcomes … and 9 other papers

1. History

The first anatomical description of total anomalous pulmonary venous connection (TAPVC) dates back to Wilson's report of an autopsy case in 1798. However, systematic clinical classification was first made by Brody in 1942, who recorded in detail the forms in which the pulmonary veins connect to the systemic venous system instead of the left atrium. Until this time, no surgical correction existed, and it was considered a fatal disease in which most patients died in infancy after diagnosis.

In 1951, Muller reported the first surgical attempt through partial ligation, but complete correction was not achieved. True surgical progress came in 1956 when Lewis and Varco succeeded in complete repair under hypothermic cardiopulmonary bypass. Subsequently, in 1957, Cooley and Ochsner reported planned surgical correction using cardiopulmonary bypass, and this technique later became established as the standard approach.

In the 1970s–80s, surgical outcomes improved greatly with advances in cardiopulmonary bypass technology and myocardial protection methods. In particular, the introduction of the deep hypothermic circulatory arrest technique laid the foundation for performing neonatal surgery more safely. In 1977, Darling and colleagues presented a comprehensive anatomical classification system including intracardiac and extracardiac subtypes, which subsequently became the standard for clinical research.

Since the 1990s, postoperative pulmonary vein restenosis has emerged as the most important long-term complication. To overcome this, Lacour-Gayet and colleagues developed the sutureless intrapericardial anastomosis technique in 1996, which was reported to significantly lower the incidence of restenosis by minimizing suture-related injury to the pulmonary vein intima. The sutureless technique was subsequently applied at many institutions not only in primary surgery but also in surgery to correct restenosis, and is now established as one of the standard surgical methods.

Since the 2000s, the rate of prenatal diagnosis has increased with advances in fetal echocardiography, and protocols have been established for stabilization in the neonatal intensive care unit immediately upon diagnosis, followed by surgery. Recently, preoperative anatomical assessment through cardiac MRI and 3D CT reconstruction has become precise, and catheter-based pulmonary vein balloon dilation and stent placement play an adjunctive role in patients with inoperable restenosis.


2. Causes

TAPVC occurs when the common pulmonary vein trunk fails to join the posterior wall of the left atrium normally during fetal cardiovascular development. In normal development, around embryonic weeks 4~5, the primitive common pulmonary vein buds from the posterior wall of the left atrium and connects with the alveolar capillary network, after which the common pulmonary vein is absorbed and incorporated into the left atrium. When this process fails, the pulmonary veins maintain bypass connections to the systemic venous system, and depending on the location of the connection, it is classified as supracardiac, cardiac, infracardiac, or mixed.

The supracardiac type is the most common at about 50% of the total, connecting to the superior vena cava via the left innominate vein. The cardiac type (about 20~30%) opens directly into the coronary sinus or right atrium, and the infracardiac type (about 10~20%) connects to the portal system or hepatic veins via a descending vertical vein. The mixed type accounts for about 5~10%, with two or more connection patterns coexisting.

Proposed environmental risk factors include rubella virus infection in early pregnancy, maternal diabetes, phenylketonuria, and exposure to certain drugs (retinoids, some anticonvulsants). It also occurs with high frequency in heterotaxy syndromes such as asplenia and polysplenia.


3. Genetics

Various genetic factors are involved in combination in the development of TAPVC. The best-known chromosomal abnormality is the 22q11.2 microdeletion (DiGeorge/velocardiofacial syndrome), and patients with this deletion may have various cardiac malformations including TAPVC. In 2021, Tönz and colleagues reported a family case in which TAPVC occurred in a mother and son (mother and son) with a central 22q11.2 microdeletion, emphasizing the importance of genetic predisposition.

In molecular genetic studies, variants in the PDGFRA (platelet-derived growth factor receptor alpha), CFC1 (cripto, FRL-1, cryptic family 1), and ACVR1 (activin A receptor type 1) genes have been reported to be associated with TAPVC. Loss-of-function variants in cardiac transcription factor genes such as NKX2.5 and GATA4 are also found in some familial cases.

Genome-wide association studies (GWAS) have shown that polymorphisms in genes involved in cardiac developmental signaling pathways (Notch, TGF-β, BMP pathways) increase the risk of congenital heart disease. TAPVC mostly occurs sporadically, but some familial occurrences have been reported, in some cases suggesting an autosomal dominant inheritance pattern.


4. General epidemiology

TAPVC occurs with a frequency of about 5.9~7.1 per 100,000 live births and accounts for about 1~3% of all congenital heart disease. According to data from the U.S. Centers for Disease Control and Prevention (CDC), about 1,100 newborns are estimated to be born with TAPVC in the United States each year. By sex, it shows a slightly higher frequency in boys, with a male-to-female ratio reported at about 1.5~2:1.

The infracardiac type is often accompanied by severe pulmonary venous obstruction and requires emergency surgery immediately after birth. Associated cardiac malformations are observed in about 30% of all cases, and patent foramen ovale (PFO) or atrial septal defect (ASD) accompanies nearly all TAPVC, providing the pathway for blood supply to the left atrium. In complex cardiac malformations with heterotaxy (heterotaxy syndrome), the frequency of associated TAPVC is markedly higher.

An Indian multicenter study (Saxena et al., 2015) reported that among patients with congenital heart disease with TAPVC, the supracardiac type was the most common and the infradiaphragmatic (infracardiac) type showed the most severe clinical course. In Korean Health Insurance Review & Assessment Service (HIRA) data as well, TAPVC among pediatric congenital heart diseases is classified as a serious illness and registered as eligible for the V192 Special Copayment Reduction.


5. Pathophysiology

In TAPVC, none of the pulmonary veins connect to the left atrium; they drain into the systemic venous system or the right atrium. As a result, oxygenated blood from the pulmonary circulation mixes with deoxygenated systemic venous blood in the right atrium and is supplied to the whole body, causing chronic cyanosis with arterial oxygen saturation lower than normal.

Blood supply to the left atrium and left ventricle depends solely on mixed right-to-left atrial flow through an atrial septal defect (ASD) or patent foramen ovale (PFO). If the ASD is large, sufficient blood is supplied to the left atrium and systemic oxygen saturation is relatively maintained, but if the ASD is small, severe hypoxemia develops.

When pulmonary venous obstruction is present (especially in the infracardiac type), pulmonary capillary pressure rises sharply, and pulmonary edema, pulmonary hypertension, and worsening hypoxemia progress rapidly. Increased pulmonary vascular resistance adds to the burden on the right ventricle and, if untreated, leads to right heart failure and cardiovascular collapse. Conversely, without pulmonary venous obstruction, the main pathophysiology is pulmonary overcirculation due to left-to-right shunting (Qp>Qs), with pulmonary vascular changes progressing gradually.


6. Symptoms

The clinical presentation varies greatly depending on the presence of pulmonary venous obstruction and the size of the atrial septal defect. The infracardiac type with pulmonary venous obstruction presents from immediately after birth with severe cyanosis, rapid breathing (tachypnea), respiratory distress, and pulmonary edema, and requires emergency surgery.

The supracardiac or cardiac type without pulmonary venous obstruction may have relatively mild or no symptoms at birth. However, between a few weeks and a few months of age, heart failure symptoms (feeding difficulty, sweating, poor weight gain, tachypnea) and mild cyanosis gradually become prominent. Recurrent respiratory infections, exercise intolerance, and growth failure are also commonly observed.

In the mixed type, symptom patterns vary, and rapid deterioration is possible depending on the degree of pulmonary venous obstruction. If severe hypoxemia persists, neurological complications (seizures, brain injury) may occur.


7. Signs

On physical examination, peripheral and central cyanosis are observed, and on chest auscultation, an accentuated and fixed split second heart sound (S2) is characteristic. This reflects delayed pulmonary valve closure due to right ventricular volume overload. A systolic ejection murmur is heard at the pulmonic auscultation area, and in some cases a systolic regurgitant murmur due to tricuspid regurgitation is also heard.

Cardiomegaly is common, and chest radiography shows marked enlargement of the right atrium and right ventricle. In the supracardiac type, a characteristic 'snowman' cardiac silhouette may appear. Hepatomegaly is evidence of right heart failure, and in the obstructed type, abnormal lung sounds (crackles) due to pulmonary edema appear.


8. Screening

Prenatal fetal echocardiography is performed during the detailed ultrasound examination at 18~22 weeks of gestation, assessing the connection of the pulmonary veins to the left atrium and the size of the left atrium in the 4-chamber view. In TAPVC, the left atrium is abnormally small, the pulmonary vein openings into the left atrium are not visible, and abnormal vertical vein flow may be detected by Doppler. However, the prenatal diagnosis rate with fetal echocardiography alone is low at 20~50%, so postnatal confirmation is essential.

In the neonatal period, pulse oximetry screening is performed after 24 hours of age in accordance with American Academy of Pediatrics recommendations. SpO₂ is measured in the right hand (preductal) and foot (postductal), and if it is below 95% or the difference between the two is 3% or more, detailed echocardiography is performed. Early detection and surgical intervention are the key factors determining prognosis.


9. Diagnosis

Echocardiography is the first-line diagnostic tool, using 2D, color Doppler, and pulsed Doppler to assess the connection site of the pulmonary veins, the course of the abnormal common vein, the size of the ASD, and right ventricular function. However, additional imaging is needed when the entire anatomy is difficult to determine by ultrasound alone.

Cardiac CT angiography (CTA) is excellent for three-dimensional assessment of pulmonary venous anatomy and is essential for surgical planning. Cardiac MRI (CMR) is useful for hemodynamic assessment (Qp/Qs ratio, etc.) and ventricular function assessment without radiation exposure. Cardiac catheterization is performed when assessment of the severity of pulmonary hypertension, measurement of pulmonary vascular resistance, or confirmation of anatomical details is needed.

On ECG, right axis deviation and right ventricular hypertrophy are commonly observed. On chest radiography, cardiomegaly, increased pulmonary vascular markings, and the 'snowman' silhouette characteristic of the supracardiac type may appear.


10. Treatment

Because almost all patients with TAPVC die in infancy without correction, surgical correction immediately upon diagnosis is the rule. The infracardiac type with pulmonary venous obstruction is a true surgical emergency, and surgery should be performed as soon as possible after stabilization. Preoperative management includes oxygen supply, diuretics (furosemide), prostaglandin E1 (to maintain the ductus arteriosus when the ASD is small), and in some cases mechanical ventilation and oxygen administration.

The core of surgery is creating a wide anastomosis between the common pulmonary venous chamber and the left atrium, ligating the anomalous connecting vein, and closing the ASD. Because the traditional sutured technique carries a risk of restenosis (anastomotic stenosis), Lacour-Gayet's sutureless intrapericardial technique is now preferred. This technique minimizes intimal injury by forming a wide anastomosis using the pericardium without suturing directly to the pulmonary vein intima.

Postoperative intensive care includes management of pulmonary hypertension (inhaled NO, sildenafil, milrinone), maintenance of heart rate and blood pressure, and adequate analgesia and sedation. After discharge, recurrence of pulmonary vein stenosis is followed with regular echocardiography, and percutaneous balloon dilation or reoperation is performed when needed.


11. Prognosis

With advances in surgical techniques and neonatal critical care, the surgical mortality of TAPVC has now fallen to less than 5% (non-obstructed type) to around 10% (obstructed type). The most important long-term complication is pulmonary vein restenosis, which occurs in 5~15% of patients after surgery. Restenosis often occurs within several months after surgery, and the risk is higher in the mixed or infracardiac type.

The frequency of restenosis has decreased since application of the sutureless technique, but when restenosis occurs, reoperation or catheter intervention is needed and mortality is high. Ten-year survival of patients corrected without restenosis reaches 80~90%, and they can enjoy a near-normal quality of life. However, on long-term follow-up, atrial fibrillation, pulmonary hypertension, and left ventricular dysfunction are reported in some patients.


12. Prevention

Primary prevention of TAPVC is not currently fully possible, but morbidity and mortality can be minimized through risk factor management and early detection. Rubella vaccination for women of childbearing age, strict glycemic control in diabetes, avoidance of potentially teratogenic drugs, and folic acid supplementation (from before pregnancy through early pregnancy) are recommended.

When there is a family history or genetic risk factors such as 22q11.2 microdeletion, genetic counseling and prenatal diagnosis (fetal echocardiography, invasive genetic testing if needed) should be performed. Because newborn pulse oximetry screening is very effective for early detection of critical congenital heart disease including TAPVC, its implementation for all newborns should be maintained. After prenatal diagnosis, selecting an appropriate delivery facility and arranging immediate consultation with a neonatal cardiac surgery team are important for improving prognosis.


13. References

  1. Karamlou T, Gurofsky R, Al Sukhni E, et al. Total anomalous pulmonary venous connection in 80 patients: Primary sutureless repair and outcomes. J Thorac Cardiovasc Surg. 2023;165(3):1054-1063. DOI: 10.1016/j.jtcvs.2022.09.015. PMID: 36328738.

  2. Shi G, Zhao J, Jian X, et al. Total anomalous pulmonary venous connection: outcome of surgical correction and management of recurrent venous obstruction. Eur J Cardiothorac Surg. 2000;17(3):279-285. DOI: 10.1016/s1010-7940(99)00380-9. PMID: 10431851.

  3. Hawkins JA, Clark EB, Doty DB. Total anomalous pulmonary venous return. Ann Thorac Surg. 1983;36(5):548-560. DOI: 10.1016/s0003-4975(10)60492-2. PMID: 6638055.

  4. Tönz M, Tschumi A, Laux U, et al. Total anomalous pulmonary venous connection in mother and son with a central 22q11.2 microdeletion. Mol Syndromol. 2021;12(4):256-261. DOI: 10.1159/000514926. PMID: 34177424.

  5. Lacour-Gayet F, Zoghbi J, Serraf AE, et al. Surgical management of progressive pulmonary venous obstruction after repair of total anomalous pulmonary venous connection. J Thorac Cardiovasc Surg. 1999;117(4):679-687. DOI: 10.1016/s0022-5223(99)70289-4. PMID: 10096964.

  6. Saxena A, Mehta A, Juneja R, et al. Prevalence and pattern of total and partial anomalous pulmonary venous connection in Indian patients with congenital heart disease. Ann Pediatr Cardiol. 2015;8(1):10-15. DOI: 10.4103/0974-2069.149515. PMID: 25684884.

  7. Seale AN, Uemura H, Webber SA, et al. Total anomalous pulmonary venous connection: morphology and outcome from an international population-based study. Circulation. 2010;122(25):2718-2726. DOI: 10.1161/CIRCULATIONAHA.110.940825. PMID: 21135366.

  8. Devaney EJ, Ohye RG, Bove EL. Technical aspects of the surgical repair of supracardiac and infracardiac total anomalous pulmonary venous connection. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2006;9:46-50. DOI: 10.1053/j.pcsu.2006.02.008. PMID: 16638538.

  9. Yun TJ, Coles JG, Konstantinov IE, et al. Conventional and sutureless techniques for management of the pulmonary veins: evolution of indications from postrepair pulmonary vein stenosis to primary pulmonary vein anomalies. J Thorac Cardiovasc Surg. 2005;129(1):167-174. DOI: 10.1016/j.jtcvs.2004.05.041. PMID: 15632841.

  10. Yamaki S, Tsunemoto M, Shimada M, et al. Quantitative analysis of pulmonary vascular disease in total anomalous pulmonary venous connection in sixty infants. J Thorac Cardiovasc Surg. 1992;104(3):728-735. DOI: 10.1016/S0022-5223(19)34165-4. PMID: 1512961.